<DOC>
	<DOCNO>NCT02238795</DOCNO>
	<brief_summary>Sepsis-associated Purpura fulminans ( SAPF ) rare life-threatening condition . It characterize multiple skin lesion rapidly progress necrosis gangrene . SAPF manifestation widespread clot formation small blood vessel emerge secondarily severe bacterial viral infection . The clinical presentation SAPF dominate symptom severe sepsis multiple organ failure aggravate massive skin lesion . At present , evidence-based guideline medical management SAPF . With numerous therapeutic approach use , consistent comparison efficacy . Altered role causal pathogens follow introduction meningococcal pneumococcal prophylactic vaccine also remain investigated . The goal registry comprehensive collection evaluation information concern epidemiology , morbidity , therapy outcome SAPF .</brief_summary>
	<brief_title>Sepsis-Associated Purpura Fulminans International Registry - Europe</brief_title>
	<detailed_description>Purpura fulminans clinical manifestation disseminate thrombosis dermal systemic microcirculation . This rare disease frequently associate multiple organ failure represent life-threatening condition mortality exceed 50 % . In vast proportion case , condition show emerge secondary acquire Protein C deficiency associate severe sepsis , mostly meningococcal pneumococcal origin . A consistent therapeutic approach sepsis-associated Purpura fulminans ( SAPF ) establish yet . With exaggerated pro-coagulant activity confirm key pathogenic aspect , several treatment modality aim balance restoration coagulation cascade consider . SAPF causality might substantially alter wake widespread meningococcal pneumococcal vaccination . There neither evidence-based treatment guideline comparative evaluation efficacy different therapeutic approach . The present registry aim ) large-scale data accumulation comprehensive evaluation incidence , causality current treatment strategy SAPF , b ) comparative assessment treatment strategy include include protein C supplementation c ) identification patient subgroup particular eligibility Protein C treatment , judge establish criterion disease severity assessment , ) feedback aggregate data registry contributor , thus permit quality management standard update , e ) dissemination data evaluation summary recommendation use Protein C formulation clinical routine , f ) elaboration framework SAPF treatment recommendation guideline . The registry comprise prospective , multicentric open-label data collection current state incidence management SAPF , regardless etiopathogenic background . It include comprehensive record diagnosis , morbidity management SAPF , supply form eCRFs participate center period three year .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura Fulminans</mesh_term>
	<criteria>Diagnosis sepsis Purpura fulminans Signed informed consent Premature neonate ( gestational age 36 week )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Purpura fulminans , Sepsis , Epidemiology , Morbidity , Therapy</keyword>
</DOC>